6 Quotes by Dhulsini Zoysa

It implies there is room for a counter offer.

We expect the company to be a cardiovascular powerhouse, worth more together than on a stand-alone basis.

This is standard stuff, and the numbers don't blow me away. I certainly expect there to be dozens, if not hundreds, of patients who come forward. It's premature to try to predict the ultimate disposition of the cases.

It's a slam-dunk for Boston Scientific, and I think there are implications for the rest of the industry.

Eighty dollars a share is certainly a fair price for this business that we suspect is not nearly as damaged as the media coverage would suggest. It becomes increasingly difficult for J&J to follow Boston's lead on price.

Strong leadership and better communication would likely turn it around within 18 to 24 months.